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Intrarenal synthesis of complement. During the past decade, complement proteins. In 1991, Brooimans et al reported
research has shown that the kidney has the capacity to synthe- the synthesis of complement by proximal tubular epithe-
size most of the activation pathway components of the comple- lial cells grown from normal human kidney [5]. In thement cascade. As well as implying physiological roles in local
same year, in situ hybridization studies reported byclearance of immune complexes and defense against invasive
Witte, Welch, and Beischel confirmed that the renal tu-organisms, an increasing amount of evidence indicates that
the intrarenal synthesis of complement makes an important bule was a prominent site for local complement gene
contribution in the pathogenesis of renal injury. Here we review expression in normal and diseased kidneys [6]. In 1993,
this evidence and present a case for more definitive investiga- our group at Guy’s published a series of experiments intion of these functions.
which cultured human glomerular mesangial and epithe-
lial cells were shown to be able to secrete a variety of
classic and alternative pathway components [7–9]. Mon-An article by Feucht et al in 1989 attracted attention
tinaro et al reported similar findings with mesangial cellsto the possibility that the local synthesis of complement
[10]. Several years later, Sheerin et al demonstrated thecomponents might be an inherent feature of the human
potential for glomerular endothelial synthesis of comple-kidney [1]. It described the isolation of gene transcripts
ment using a rat glomerular endothelial cell line [11].for C4 from the cortex of normal human kidney. In
Thus, the stage was set for a comprehensive descriptionthe previous year, published work by Passwell et al in
of the range and cellular origin of complement proteinsWashington (USA) found that the kidney of mice with
generated locally within normal and diseased kidneys,lupus nephritis expressed increased amounts of RNA
from mouse to humans. Today, although we have a de-message for C4, C2, C3, and factor B [2]. Moreover, they
tailed picture of the renal complement system, includingshowed that tissue slices prepared from the inflamed
recent quantitation of the contribution made by thekidneys of these mice could incorporate amino acids
transplanted kidney to the pool of circulating C3 [12],present in the culture medium into complement proteins,
we have only a limited knowledge about the functionalindicating that local complement gene expression could
importance of local complement synthesis, with particu-result in significant protein synthesis. A strong possibility
lar regard to disease. In this review, against a backgroundwas that infiltrating cells, which were abundant in the
of incontrovertible evidence showing that complementnephritic tissue, had produced these components. This
plays a role in the pathogenesis of renal disease [13, 14],was because previous work in the principal author’s labo-
we consider the current evidence that suggests local pro-ratory and subsequently in several other laboratories
duction of complement may be contributing to renalhad already shown that cells of bone marrow origin (for
injury in a variety of conditions.example, macrophages and monocytes) were capable of
producing a wide range of complement components
[3, 4]. However, a number of other research groups,
COMPLEMENT SYSTEM AND MECHANISMSnamely in Leiden, Toronto, London, and Bari, subse-
OF TISSUE INJURYquently set out to investigate which, if any, indigenous
There are several ways in which complement activa-cell types in the kidney had the capacity to synthesize
tion can lead to tissue injury (Fig. 1). These have been
reviewed extensively elsewhere [15]. First, the cleavage
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of C3 and then C5 generates small biologically activecomplement, renal complement system, pathogenesis of renal disease,
immune complexes. peptides, C3a and C5a. These stimulate the vascular and
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Fig. 1. The complement cascade. The central step of the complement cascade involves the cleavage of C3. This is achievable by activation of the
classic, alternative, or lectin pathways. Activation of these pathways generates converting enzyme complexes that cleave C3. Cleavage of C3 and
subsequently C5 results in the generation of anaphylatoxins (C3a and C5a) and MAC (C5b-9). The large cleavage product C3b and its degradation
products (iC3b or C3 dg) mediate a number of biologically important effects including enhancement of T-cell and B-cell function and disposal of
immune complexes and apoptotic cells. Abbreviations are: MBL, mannan-binding lectin; MASP, MBL-associated serine protease.
brane attack complex (MAC; C5b-9). The MAC forms is the enhancement of the immune response caused by
breakdown fragments of C3 (for example, C3b and C3d)pores in cells resulting in cell activation or, at higher
concentration, to cell death by lysis. Sublytic doses of binding to antigen, greatly lowering the threshold for stim-
ulation of antigen-specific lymphocytes [19–21]. TheseMAC can activate renal parenchymal cells, which then
release proinflammatory cytokines, reactive oxygen spe- mechanisms are initiated by cleavage of C3 by converting
enzymes. These enzyme complexes are generated by an-cies, vasoactive chemicals, and profibrotic factors [16–18].
In addition to initiating the terminal pathway of comple- tibody and non–antibody-mediated mechanisms acting
through the classic, alternative, and lectin complementment activation, C3b and C4b deposition on target cells
increases the potential for interaction with inflammatory pathways (Fig. 1). Complement-regulatory proteins, which
can be soluble (for example, C4 binding protein, factorcells bearing receptors for these ligands [15]. A fourth,
more recently elucidated mechanism of potential injury H) or cell bound (for example, decay accelerating factor,
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Table 1. Differential detection of complement gene expression in cleavage of factor B and thus contributes to alternative
normal human kidney [24]
pathway function. Clustering of the components of the
Cortex Glomeruli Tubules Medulla activation pathways in the tubule may act as a front line
C1q 11 11 11 11 defense against pathogens. Several types of nonrenal cell
C2 1 1/2 11 1 such as macrophages, neural cells, and fibroblasts express
C3 1 1/2 11 1/2
the terminal (C5-C9) as well as activation pathway com-C4 1 1 11 1
Factor B 1 1/2 1/2 1 ponents [3, 28, 29]. The expression of terminal pathway
Factor D 1 11 11 1 components in renal cells has not been described.
Factor H 1 1 11 1
As indicated earlier, four types of resident kidney cellProperdin 1 11 1/2 1/2
are capable of synthesizing complement proteins whenRelative expression of RT-PCR product obtained with RNA from fractionated
renal tissue based on 10 subjects. Symbols are: (1) detected, (11) strongly grown in tissue culture. Their complement products are
detected, (1/2) weakly detected. shown in Table 2. In general, the secretion of C3 by
such cells occurs spontaneously and may approach levels
comparable with those produced by cultured hepatoma
cells. In contrast, the expression of C4 is often weaklyCD59), block the early cleavage steps of C3 and C5 or
detected in cultured cells, even though the signal derivedinhibit the assembly of MAC, preventing self-injury by
from tissue mRNA may be strong. This discrepancy be-background or heightened complement activity.
tween in vivo and in vitro expression may be due to
rapid loss of ability to synthesize C4 in vitro, as noticed
RANGE AND CELLULAR ORIGIN OF in monocyte studies [38]. Factor B is also weakly detected
COMPLEMENT COMPONENTS PRODUCED in vitro. However, many stimulators, including cytokines,
BY THE KIDNEY growth factors, immune complexes, serum proteins, and
human cytomegalovirus, can increase the expression ofThe main source of circulating complement is the liver,
as shown after liver transplantation when the plasma C3 C3, C4, and factor B by cultured cells (Table 2). Glomer-
ular endothelial cells, in contrast with renal epithelialallotype becomes that of the donor. However, smaller
but significant amounts of complement components are and mesangial cells, are less well studied because it has
been very difficult to isolate and grow the cells in culture.produced in other organs, such as the brain, blood ves-
sels, lungs, intestine, joints, and skin as well as the kidney However, Sheerin et al demonstrated the production of
C3 by transformed rat glomerular endothelial cells [11].[22]. Naughton et al estimated that approximately 10%
of circulating C3 arises from sources other than the liver Complement is an acute phase protein in which syn-
thesis rapidly increases during infection or inflammation.[23]. More recently, a study of the conversion of one C3
allotype to another following kidney transplantation has The responsive nature of renal complement synthesis is
illustrated by the finding in allograft recipients that thesuggested that about 5% of circulating C3 is derived
from the single donor kidney [12]. level of circulating donor-derived C3 is increased during
episodes of rejection [12]. Numerous factors have beenA comprehensive range of complement genes are ex-
pressed in the kidney, including most components of the shown to regulate the production of complement by re-
nal cells (Table 2). The effects of some of these signalsactivation pathways. Our current state of knowledge is
summarized in Table 1 [24]. It can be seen that there are are tissue specific, and the response may even vary with
different cell types in the same tissue. For example, in-regional differences in complement mRNA expression
within the kidney. The main components of complement terleukin-1 (IL-1) may induce a twofold to threefold
increase in the renal expression of C2 in mice, but has nosynthesized in the liver (C2, C4, C3, and factor B) are
more strongly detected in the renal cortex consisting effect on hepatic synthesis of C2 [39]. Another example is
tumor necrosis factor-a, which regulates the transcrip-mainly of tubules, whereas some components that are
primarily produced at extrahepatic sites (for example, tion of C3 in glomerular endothelial cells [11], but has
no such effect in glomerular mesangial cells [7]. TheC1q and factor D) are detected strongly in glomeruli.
The reason for this differential distribution is unknown, cytokines IL-2 and interferon-g (IFN-g) appear to play
a major role in regulating the production of C3 and C4but it suggests that certain factors have a specialized
function in the glomerulus. For example, C1q, which by proximal tubular cells [5, 37]. Furthermore, IFN-g
induces changes in renal gene transcription while in he-is synthesized mainly in mononuclear phagocytes and
epithelial cells, has been suggested to play an important patocytes may act at the level of RNA translation to
increase local complement synthesis [8, 23]. This localrole in the clearance of immune complexes and apoptotic
bodies in the kidney [25–27]. Local expression of C1q variation in the regulation of complement may allow fine
tuning of tissue levels expressed without alteration ofcould have a kinetic advantage over deposition of a circu-
lating component. Factor D, on the other hand, which circulating levels.
In addition to the complement activation pathwayis synthesized primarily by adipocytes, participates in the
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Table 2. Complement synthesis in cells of renal origin
Cell type Factors Stimulators References
Glomerular epithelial C3 IFN-g [8]
C4 IFN-g [9]
Glomerular mesangial C2 HCMV [30]
C3 IFN-g, Immune complex, IL-1 [7, 31, 32]
C4 IFN-g [7, 33]
FB HCMV, IL-1, TNF-a, IFN-g [30, 33]
FH IFN-g [32]
Glomerular endothelial C3 TNF-a [11]
Proximal tubular epithelial C2 IFN-g [34]
C3 IL-2, Serum proteins, IL-1 [5, 35, 36]
C4 IFN-g [37]
Factor H IFN-g [34]
Factor B IL-1 [36]
Abbreviations are: IFN-g, interferon-gamma; HCMV, human cytomegalovirus; IL-1, interleukin-1; IL-2, interleukin-2; TNF-a, tumor necrosis factor-a.
components, a number of complement regulatory proteins, pression over time, and (2) clinical biopsy studies, which
provide a cross-sectional view at different stages of dis-particularly membrane-bound proteins, are synthesized
within the kidney [40–44]. These include decay-acceler- ease. In general, these have focused on C3 and C4 be-
cause of the pivotal role of these components in comple-ating factor (DAF/CD55), membrane cofactor protein
(MCP/CD46), complement receptor type 1 (CR1/CD35), ment activation. The main findings are summarized in
Tables 3 and 4. Several general conclusions can be made:and MAC inhibition factor (MACIF/CD59). DAF, MCP,
and CR1 inhibit complement activation at the level of the (1) In experimentally induced nephritis, there is an early
increase in the glomerular expression of C3 and C4. (2)C3 and C5 converting enzyme complexes, while CD59
prevents the formation of the MAC. The distribution of This change occurs in glomerular epithelial cells, parietal
epithelial cells, or mesangial cells, according to the pri-these inhibitory proteins in normal and diseased kidneys
has been comprehensively studied and is the subject of mary site of the immune attack. (3) Following the glo-
merular insult, there is a progressive increase in the tubu-excellent recent reviews by Nangaku, Johnson, and
Couser [45, 46]. These and other groups have found that lar epithelial expression of C3 and C4. (4) With patient
biopsy material, taken unavoidably at various stages ofcomplement regulatory proteins are widely expressed in
the glomeruli and renal tubules, the level of expression evolution of renal disease, there is predominant tubular
expression of C3 and C4. The level of C3 gene expressionof these molecules varying with the anatomical segment
or cell type of the kidney [40, 44]. The renal tubule is broadly correlates with the severity of tissue injury,
where studies have paid attention to this factor.relatively deficient in DAF and CD59, helping to explain
the vulnerability of the renal tubule to complement at-
tack [44, 47]. Expression of these molecules is up-regu- NEPHRITIS
lated during the activation of complement [48], as occurs
In a rat model of membranous glomerulonephritisin a number of forms of renal disease [40, 43, 49–51]. Not
(passive Heymann nephritis), glomerular injury was ac-surprisingly, overexpression of complement regulatory
companied by enhanced glomerular expression of theprotein in mice markedly ameliorates nephrotoxic serum
transcripts for C3 and C4 [54, 55]. This predominantlynephritis [52]. This indicates that complement regulatory
occurred in the podocytes but also involved the mesan-proteins play a protective role against complement-medi-
gial areas, as shown by in situ hybridization techniques.ated renal injury. The kidney therefore has a set of posi-
Tubular expression of complement was also induced fol-tive and negative internal controls with the ability to
lowing the glomerular injury. Moreover, the overall levelinfluence complement activation on the renal structures.
of C3 mRNA expression by semiquantitative polymerase
chain reaction (PCR) correlated with the severity of in-
EXPRESSION OF NATIVE COMPLEMENT jury (proteinuria) [54]. Similarly, with a mouse model of
COMPONENTS IN INJURED KIDNEY crescentic glomerulonephritis (generated by a single
dose of antiglomerular basement membrane antibody),A number of studies have examined complement gene
expression in injured kidney, defining the extent and site competitive PCR showed a 15-fold rise in the level of
C3 transcript (abstract; Sheerin et al, J Am Soc Nephrolof local complement gene expression in renal disease.
These studies can be divided into (1) experimental stud- 10:537A, 1999). This was located mainly in the tubular
epithelium by 14 days after the disease induction (unpub-ies, which have investigated local complement gene ex-
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Table 3. Animal studies of local complement synthesis in the kidney
Disease model Factors Findings Location of complement synthesis References
SLE
MRL lpr/lpr mice with C3, C2, C4 Increased expression correlating Glomerulus; infiltrating macrophages [2]
spontaneous lupus nephritis and factor B with progressive disease
(NZB 3 NZW) F1 mice with C3, C2, C4 Increased expression correlating [53]
spontaneous lupus nephritis and factor B with progressive disease
Membranous nephropathy
Passive Heymann nephritis (rats) C3 Increased expression correlating Mesangial and glomerular epithelial [54]
with progressive proteinuria cells; weak expression in tubular
over 14 days epithelial cells
Passive Heymann nephritis (rats) C4 Increased expression correlating Glomerular epithelial and proximal [55]
with progressive proteinuria tubular cells
Anti-GBM disease
Murine model C3 Increased expression over Predominantly by tubular cells, but a
10–14 days also by glomerular epithelial and
mesangial cells
Transplantation
Rat kidney transplantation C3 Initial increase in expression Vessel wall and mesangial cells follow- [56]
(allografts and isografts) both isografts and allografts, ing reperfusion; allografts subse-
and subsequent increase only quently demonstrated increased
in allografts expression in tubular epithelial
cells, parietal epithelial cells, vessel
walls and some infiltrating cells
Abbreviations are: SLE, systemic lupus erythematosus; Anti-GBM disease, anti-glomerular basement membrane disease.
a Sheerin et al (unpublished data)
lished data). Two spontaneous mouse models of lupus that enhancement of tubular complement gene expres-
sion is a consequence of glomerular disease.nephritis showed up-regulation of C3, C4, and factor B
at protein and mRNA levels, coincident with the devel- Two recent studies from Schena’s group have evalu-
ated the clinical utility of measuring complement mRNAopment of renal disease [2, 53]. Altered expression did
not occur in the liver, suggesting the local expression was as an index of progressive glomerular disease [61, 62].
The first study, in patients with IgA nephropathy, exam-functionally relevant to the observed organ pathology.
Complement mRNA was mainly located in tubular epi- ined the hypothesis that the level of C3 PCR product
derived by renal biopsy correlated with the severity ofthelial cells and the cellular infiltrate [53]. Thus, experi-
mental models of kidney disease, both spontaneous and the disease. An elevated C3 level distinguished those
patients with increased proteinuria, interstitial damage,induced, demonstrate a shift in complement gene expres-
sion away from the primary site of injury to the tubule. and glomerular changes. However, there was no clear
relationship between renal C3 expression and serum cre-Analysis of human glomerular disease tells much the
same story, although the biopsies reported are from a atinine. A study of 22 patients with membranous ne-
phropathy by the same authors also suggested a positiveheterogeneous mix of cases in each disease group. Welch,
Beischel, and Witte examined biopsies from 23 patients relationship between C3 gene expression and progres-
sive disease [62]. Similarly, the intensity of C3 expressionwith a variety of glomerular and interstitial disorders
[6, 57]. They concluded that the renal tubule was an at both the glomerular and tubulointerstitial level corre-
lated with the severity of glomerular injury [62].important site for complement synthesis in many of these
conditions. A prospective series of 41 biopsies analyzed The putative link between complement and chronic
renal disease is an interesting one. Several years agoby semiquantitative polymerase chain reaction (PCR)
showed that 55% of the patients with immune complex Nath, Hostetter, and Hostetter suggested that comple-
ment activation on the renal tubule might contribute toglomerulonephritis demonstrated increased expression
of C3. Biopsies from patients with interstitial nephritis tubular damage [65]. This notion has been reinforced by
work showing that renal tubular cells can spontaneouslyexhibited the greatest increases in C3 expression [58].
This suggests that the response to an immunologic insult activate complement and then undergo proinflammatory
changes [16]. Complement inhibitory studies using ad-plays a decisive part in up-regulating local complement
synthesis. Miyazaki et al performed a series of elegant ministered [66, 67] or genetically overexpressed comple-
ment receptors [68] also support this view. A logicalin situ hybridization studies in patients with IgA ne-
phropathy and lupus nephritis [49, 59]. Their findings extension of this hypothesis is that local overproduction
of C3 by the renal tubules themselves may contribute tosubstantiate the importance of glomerular C3 synthesis
during the evolution of these conditions, and again show tubulointerstitial injury. Furthermore, Tang et al have
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Table 4. Clinical studies of local renal complement synthesis
Diseases Factors Analysis Findings References
MCGN (N 5 1) and lupus nephritis C4 Northern analysis and C4 only expressed in tubular epithelial cells; no differ- [6]
(N 5 1) in situ hybridization ence between healthy and diseased kidneys
Glomerulonephritis (N 5 9) and C3, C4 Northern analysis and Up-regulation of C3 expression in the tubules correlat- [57]
interstitial nephritis (N 5 6) in situ hybridization ing with the pattern of glomerular disease; no upreg-
ulation in C4 expression in disease
Glomerulonephritis (N 5 20) and C3 RT-PCR Increased C3 expression in immune-mediated GN, [58]
interstitial nephritis (N 5 4) and in interstitial nephritis, but not in nonimmune
glomerular injury
IgA nephropathy (N 5 15) and lupus C3 In situ hybridization Increased C3 expression in immune-mediated GN in [59]
nephritis (N 5 5) mesangial cells, glomerular epithelial and parietal
epithelial cells, and tubular epithelial cells; some
staining also noted in infiltrating mononuclear cells
IgA nephropathy (N 5 10) and other C3, C4, In situ hybridization Predominant expression of C3 and factor B in the [60]
immune-mediated nephropathy factor B tubular epithelial cells and to a lesser extent in parietal
(N 5 7) epithelial cells; no correlation of C4 with disease
IgA nephropathy (N 5 25) C3 RT-PCR and in situ C3 expressed in 56% of patients, particularly in severe [61]
hybridization disease; predominant expression by tubular cells,
also in glomerular crescents
Membranous nephropathy (N 5 22) C3 In situ hybridization C3 expressed in 77% of biopsies by tubular and [62]
glomerular parietal epithelial cells; expression cor-
related with disease severity and urinary C5b-9 levels
Transplantation (N 5 30) C3 RT-PCR and Up-regulation of C3 expression in association with [63]
immunofluorescence rejection
Transplantation (N 5 9) C3 Allotype specific Donor derived complement detected in 66% predomi- [64]
RT-PCR and im- nantly in the tubules, but also in glomeruli
munofluorescence
Abbreviation is: MCGN, mesangiocapillary glomerulonephritis.
shown that serum protein applied to the luminal surface C3, sufficient to spill over into the recipient circulation
and urine [63, 64, 70]. During transplant rejection, theof proximal tubular epithelial cells increases the basolat-
local synthesis of C3 is increased mainly in the tubulareral secretion of C3 several-fold [35]. Thus, lateral secre-
epithelial cells at their basolateral surface [70]. More-tion of C3 stimulated by supraphysiological levels of
over, the expression of C3f by the donor kidney is associ-protein in the tubular lumen might amplify the detrimen-
ated with an increased risk of late renal dysfunction,tal effects of complement on the tubules and interstitium.
providing a clue as to the detrimental effect that local
C3 synthesis could have on the transplanted kidney [64].
TRANSPLANTATION Although infiltrating cells may also contribute to the
Important qualitative and quantitative information re- local production of complement, in general, the expres-
garding the significance of local complement expression sion of C3 by infiltrating cells is overshadowed by intrin-
has come from transplantation studies in rodents and sic expression.
humans. Syngeneic rat kidney transplants demonstrate
a burst of C3 mRNA expression located in the glomeruli
FUNCTIONAL INTERPRETATIONand blood vessels [56]. This may be an effect of ischemia/
Protectionreperfusion injury [69] on the blood vessel wall. Allo-
grafts show a secondary wave of complement gene ex- The coordinate expression of multiple components of
pression in the kidney tubules, which coincides with in- complement at the same site, under the control of com-
filtration by leukocytes and is associated with the local mon regulatory stimuli, argues in favor of a physiological
expression of cytokines such as interleukin-2 (IL-2) and role for intrarenal complement synthesis. One such role
interferon-g (IFN-g) [56]. With clinical transplantation, may be to facilitate the clearance of glomerular immune
a valuable approach has been to investigate the different complexes. Indeed, patients with inherited complement
allelic forms of C3 (C3f and C3s). Analysis of C3f nega- deficiencies, particularly of the early components, dis-
tive recipients of a C3F positive kidney has enabled (1) play reduced clearance of immune complexes and a ten-
allele-specific detection of donor C3 mRNA and protein dency to accumulate these in the glomerulus [71]. Al-
in graft biopsies and (2) allele-specific measurement of though most immune complexes are cleared in the liver
donor C3 in the recipient serum and urine. Using these or spleen, the kidney is also an important organ for
approaches, Andrews et al showed that the donor kidney immune complex handling. With its large blood flow
and filtration barrier function, the glomerular basementexhibits substantial potential for the local synthesis of
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membrane forms a charge and size selective trap. Fur- role for local complement synthesis. Much work is
needed to confirm these initial results and to extendthermore, some immune complexes are formed in situ
at the glomerular basement membrane and need to be these studies to a broader range of physiological and
pathological functions.effectively removed. Complement-deficient mice appear
to have impaired glomerular handling of complexes that
form in situ between antibody and planted antigen [72].
CONCLUSION
Although systemic complement is undoubtedly impor-
The ability to synthesize complement components ap-tant for efficient immune complex handling, it is likely
pears to go back to simple creatures such as sea urchinsthat local complement synthesis at the site of formation
and jawless fish, as represented in modern day descen-or deposition of immune complexes might facilitate their
dants of these organisms [76]. Organs such as the kidneyremoval, maintaining the integrity of the glomerular bar-
seem to have taken on specialized functions of comple-rier. The observation that immune complex binding to
ment that may provide the organ with protection againstmesangial cells stimulates the production of C3 lends
pathogenic stimuli. One consequence is that excessivesupport to this idea [31]. Besides increasing the solubility
expression of these components may result in or addof immune complexes, the split product C3b enhances
to inflammatory injury. Organ transplantation betweentheir uptake by phagocytic cells (for example, mesangial
complement-sufficient and -deficient animals offers acells) [73]. Moreover, recent studies suggest that iC3b
means to dissect the importance of these possible func-and C1q mark the surface of apoptotic cells, enhancing
tions, and the early indications are consistent with atheir physiological clearance [26, 74]. Potentially, the
pathogenic role for local synthesis of complement insecretion of early complement components by the tubu-
renal disease. The analysis of these questions will belar epithelium may also serve to enhance the barrier
further enhanced once it becomes possible to routinelyfunction of the tubule as a defense against invasive micro-
engineer animals with tissue or cell-specific deficienciesorganisms. Indeed, complement products that serve in
of these components.this role are normally too large to cross the glomerular
filtration barrier. However, as shown in a recent study, Reprint requests to Dr. Steven H. Sacks, Department of Nephrology
and Transplantation, 5th Floor, Thomas Guy House, Guy’s Hospital,complement components are detected in the urine [62, 75].
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